You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Moodys
Colorcon
McKinsey
Merck

Last Updated: October 31, 2020

DrugPatentWatch Database Preview

Claims for Patent: 9,278,123

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,278,123
Title:Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid
Abstract: The present invention relates to solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and their use in medicine.
Inventor(s): Sauerberg; Per (Farum, DK), Bjerregaard; Simon (Hilleroed, DK), Nielsen; Flemming Seier (Roskilde, DK)
Assignee: Novo Nordisk A/S (Bagsvaerd, DK)
Application Number:13/994,262
Patent Claims: 1. A solid composition for oral administration comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid, wherein the amount of said salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid is in the range of 0.8-1.3 mmol, and the GLP-1 agonist is N-epsilon26-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxyheptadecanoylam- ino) butyrylamino] ethoxy} ethoxy)acetylamino] ethoxy} ethoxy)acetyl] [Aib8, Arg34] GLP-1(7-37).

2. The composition according to claim 1, wherein said composition is in the form of a tablet.

3. The composition according to claim 1, wherein the amount of the GLP-1 agonist is in the range of 5 to 20 mg.

4. The composition according to claim 1, wherein said salt of N-(8-(2-hydroxybenzoyl) amino)caprylic acid is selected from the group consisting of the sodium salt, potassium salt and calcium salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid.

5. The composition according to claim 4, wherein the amount of the GLP-1 agonist is in the range of 5 to 20 mg.

6. The composition according to claim 4, wherein said salt of N-(8-(2-hydroxybenzoyl) amino)caprylic acid is sodium N-(8-(2-hydroxybenzoyl)amino)caprylate (SNAC).

7. The composition according to claim 6, wherein the amount of the GLP-1 agonist is in the range of 5 to 20 mg.

8. A method for treatment of type II diabetes or obesity comprising administering a composition according to claim 1 to a patient in need thereof.

9. A solid composition for oral administration comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid, wherein the amount of said GLP-1 agonist is in the range of from 5 to 20 mg, and the GLP-1 agonist is N-epsilon26-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxyheptadecanoylam- ino) butyrylamino]ethoxy}ethoxy)acetylamino]ethoxy}ethoxy)acetyl][Aib8, Arg34]GLP-1(7-37).

10. The composition according to claim 9, wherein said salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid is selected from the group consisting of the sodium salt, potassium salt and calcium salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid.

11. The composition according to claim 10, wherein said salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid is sodium N-(8-(2-hydroxybenzoyl)amino)caprylate (SNAC).

12. The composition according to claim 11, wherein the amount of SNAC is in the range of 250 mg to 400 mg.

13. The composition according to claim 11, wherein the amount of SNAC is 300 mg.

14. The composition according to claim 9, wherein said composition is in the form of a tablet.

15. A method for treatment of type II diabetes or obesity comprising administering a composition according to claim 9 to a patient in need thereof.

16. A solid composition for oral administration comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid, wherein the amount of said salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid is in the range of 0.6-2.1 mmol, and the GLP-1 agonist is N-epsilon26-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxyheptadecanoylam- ino) butyrylamino]ethoxy}ethoxy)acetylamino]ethoxy}ethoxy)acetyl][Aib8, Arg34]GLP-1(7-37), wherein the amount of the GLP-1 agonist is in the range of 5 to 20 mg.

17. The composition according to claim 16, wherein said salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid is selected from the group consisting of the sodium salt, potassium salt and calcium salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid.

18. The composition according to claim 17, wherein said salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid is sodium N-(8-(2-hydroxybenzoyl)amino)caprylate (SNAC).

19. The composition according to claim 18, wherein said composition is in the form of a tablet.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Merck
AstraZeneca
Express Scripts
Baxter
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.